Allen L. Cohn

Oct 11, 2024 | digitalcommons.library.tmc.edu | Vicky Makker |Matthew Taylor |Carol Aghajanian |Allen L. Cohn

BACKGROUND: Lenvatinib plus pembrolizumab demonstrated clinically meaningful benefit in patients with previously treated advanced endometrial carcinoma in Study 111/KEYNOTE-146 (NCT02501096). In these exploratory analyses from this study, we evaluated the associations between clinical outcomes and gene expression signature scores and descriptively summarized response in biomarker subpopulations defined by tumor mutational burden (TMB) and DNA variants for individual genes of interest.

Mar 1, 2024 | jitc.bmj.com | Heinz-Josef Lenz |Aparna R. Parikh |David R. Spigel |Allen L. Cohn

DiscussionPhase 2 results from the CheckMate 9X8 trial did not demonstrate a statistically significant improvement in median PFS with nivolumab plus SOC versus SOC in the first-line treatment of patients with mCRC. The PFS curves overlapped before separating at approximately 12 months; nivolumab plus SOC showed numerically higher PFS rates after 12 months compared with SOC. PFS subgroup analyses showed a numerical trend favoring nivolumab plus SOC across multiple subgroups (HR<1).

Jan 1, 2024 | jitc.bmj.com | Vicky Makker |Matthew Taylor |Carol Aghajanian |Allen L. Cohn

Clinical/translational cancer immunotherapy Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146 Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

Apr 6, 2023 | thelancet.com | David Chang |Virginia Oncology Associates |Tim Larson |Allen L. Cohn

SummaryBackgroundAnti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with microsatellite stable/mismatch repair-proficient metastatic colorectal cancer.